Granisetron

DRUG INFORMATION

  ADULT
    - Treatment of postoperative nausea and vomiting ( 2.2 ): Recommended dosage is 1
      mg, undiluted, administered intravenously over 30 seconds. 2.1 Prevention of
      Chemotherapy-Induced Nausea and Vomiting Adult Patients The recommended dosage for
      granisetron hydrochloride injection is 10 mcg/kg administered intravenously within
      30 minutes before initiation of chemotherapy, and only on the day(s) chemotherapy
      is given.
      Source: US FDA label for granisetron (Granisetron), section 'dosage and
      administration', retrieved 2026-08-29
    - Prevention of Chemotherapy-Induced Nausea and Vomiting Adult Patients The
      recommended dosage for granisetron hydrochloride injection is 10 mcg/kg
      administered intravenously within 30 minutes before initiation of chemotherapy,
      and only on the day(s) chemotherapy is given.
      Source: US FDA label for granisetron (Granisetron), section 'dosage and
      administration', retrieved 2026-08-29
    - Prevention of chemotherapy-induced nausea and vomiting ( 2.1 ): Recommended dosage
      is 10 mcg/kg intravenously within 30 minutes before initiation of chemotherapy
      Pediatric patients (2 to 16 years): Recommended dosage is 10 mcg/kg Prevention of
      postoperative nausea and vomiting ( 2.2 ): Recommended dosage is 1 mg, undiluted,
      administered intravenously over 30 seconds, before anesthetic induction or
      immediately before reversal of anesthesia.
      Source: US FDA label for granisetron (Granisetron), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - Chemotherapy-Induced Nausea and Vomiting [See Dosage and Administration ( 2 )] for
      use in chemotherapy-induced nausea and vomiting in pediatric patients 2 to 16
      years of age. Safety and effectiveness in pediatric patients under 2 years of age
      have not been established. Postoperative Nausea and Vomiting Safety and efficacy
      have not been established in pediatric patients for the prevention of
      postoperative nausea and vomiting (PONV).
      Source: US FDA label for granisetron (Granisetron), section 'pediatric use',
      retrieved 2026-08-29
    - Prevention of chemotherapy-induced nausea and vomiting ( 2.1 ): Recommended dosage
      is 10 mcg/kg intravenously within 30 minutes before initiation of chemotherapy
      Pediatric patients (2 to 16 years): Recommended dosage is 10 mcg/kg Prevention of
      postoperative nausea and vomiting ( 2.2 ): Recommended dosage is 1 mg, undiluted,
      administered intravenously over 30 seconds, before anesthetic induction or
      immediately before reversal of anesthesia.
      Source: US FDA label for granisetron (Granisetron), section 'dosage and
      administration', retrieved 2026-08-29
    - Prevention of Chemotherapy-Induced Nausea and Vomiting Adult Patients The
      recommended dosage for granisetron hydrochloride injection is 10 mcg/kg
      administered intravenously within 30 minutes before initiation of chemotherapy,
      and only on the day(s) chemotherapy is given.
      Source: US FDA label for granisetron (Granisetron), section 'dosage and
      administration', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - No kidney-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for granisetron (Granisetron),
      retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for granisetron (Granisetron),
      retrieved 2026-08-29

  PREGNANCY   [ CAUTION ]
    The label allows it only when the benefit is judged to outweigh the risk. Read the
      quote below.
    - Pregnancy Category B Reproduction studies have been performed in pregnant rats at
      intravenous doses up to 9 mg/kg/day (54 mg/m 2 /day, 146 times the recommended
      human dose based on body surface area) and pregnant rabbits at intravenous doses
      up to 3 mg/kg/day (35.4 mg/m 2 /day, 96 times the recommended human dose based on
      body surface area) and have revealed no evidence of impaired fertility or harm to
      the fetus due to granisetron.
      Source: US FDA label for granisetron (Granisetron), section 'pregnancy', retrieved
      2026-08-29
    - There are, however, no adequate and well-controlled studies in pregnant women.
      Source: US FDA label for granisetron (Granisetron), section 'pregnancy', retrieved
      2026-08-29
    - Because animal reproduction studies are not always predictive of human response,
      this drug should be used during pregnancy only if clearly needed.
      Source: US FDA label for granisetron (Granisetron), section 'pregnancy', retrieved
      2026-08-29

  BREASTFEEDING   [ CAUTION ]
    The label allows it only when the benefit is judged to outweigh the risk. Read the
      quote below.
    - It is not known whether granisetron is excreted in human milk.
      Source: US FDA label for granisetron (Granisetron), section 'nursing mothers',
      retrieved 2026-08-29
    - Because many drugs are excreted in human milk, caution should be exercised when
      granisetron hydrochloride injection is administered to a nursing woman.
      Source: US FDA label for granisetron (Granisetron), section 'nursing mothers',
      retrieved 2026-08-29
    - ( 8.1 ) Nursing mothers: Caution should be exercised when administered to a
      nursing woman.
      Source: US FDA label for granisetron (Granisetron), section 'use in specific
      populations', retrieved 2026-08-29